Takeda teams with enGene for gastrointestinal R&D

Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. Under the agreement, enGene will develop two treatments matching up to Takeda-selected targets through preclinical studies, and the major drugmaker will take the reins from there, promising its partner an upfront payment and milestones tied to R&D. Release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.